MAYNE PHARMA GROUP LIMITED — Director's Dealing 2011

May 29, 2011

Appendix 3Y Change of Director’s Interest Notice

Rule 3.19A.2

Appendix 3Y

Change of Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Mayne Pharma Group Limited
ABN	76 115 832 963

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Roger Aston
Date of last notice	20 January 2011

Part 1 - Change of director’s relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

Direct or indirect interest	Direct interest
Nature of indirect interest(including registered holder)Note: Provide details of the circumstances giving rise to the relevantinterest.	Direct interest (1)Newtonmore Biosciences Pty Ltd (2)Newtonmore Super Fund (3)
Date of change	18 April 2011
No. of securities held prior to change	3,820,000 Ordinary Shares (1)4,251,000 Ordinary Shares (2)1,000,000 Ordinary Shares (3)25,000Unlisted options for ordinaryshares @ 60 cents expiring 17April 2011 (1)625,000Unlisted options for ordinaryshares @ 60 cents expiring 17April 2012 (1)1,900,000 Unlisted options for ordinaryshares @ 27 cents expiring 31December 2012(1)
Class	Unlisted options for ordinary shares @ 60cents expiring 17 April 2011 (1)
Number acquired	Nil

• See chapter 19 for defined terms.

01/01/2011 Appendix 3Y Page 1

Appendix 3Y Change of Director’s Interest Notice

Number disposed	25,000 options expired	25,000 options expired
Value/Consideration	Nil
Note: If consideration is non-cash, provide details and estimated
valuation
No. of securities held after change	3,820,000 Ordinary Shares (1)
	4,251,000	Ordinary Shares (2)
	1,000,000	Ordinary Shares (3)
	625,000	Unlisted options for ordinary
		shares @ 60 cents expiring 17
		April 2012 (1)
	1,900,000	Unlisted options for ordinary
		shares @ 27 cents expiring 31
		December 2012 (1)
Nature of change	Options expired
Example: on-market trade, off-market trade, exercise of options,
issue of securities under dividend reinvestment plan, participation in
buy-back

Part 2 – Change of director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract Nature of interest Name of registered holder (if issued securities) Date of change No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed Interest acquired Interest disposed Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation Interest after change

• See chapter 19 for defined terms.

Appendix 3Y Page 2

01/01/2011

Appendix 3Y Change of Director’s Interest Notice

Part 3 –[+] Closed period

Part 3 –+Closed period
Were the interests in the securities or contracts detailedabove traded during a+closed period where prior writtenclearance was required?	No approval required to allowoptions to lapse.
If so, was prior written clearance provided to allow the tradeto proceed during this period?	No approval required for thechange in interest.
If prior written clearance was provided, on what date was thisprovided?	N/A

• See chapter 19 for defined terms.

01/01/2011 Appendix 3Y Page 3